Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.03 | 0.00 | 0.07 | 0.10 | 0.07 | 0.10 | 0.06 | 0.03 | 0.05 | 0.03 | 0.08 | 0.04 |
| Operating Profit | -0.03 | 0.00 | -0.07 | -0.10 | -0.07 | -0.10 | -0.06 | -0.03 | -0.05 | -0.03 | -0.08 | -0.04 |
| OPM % | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.01 | 0.12 |
| Interest | 0.03 | 0.03 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.06 | -0.03 | -0.04 | -0.13 | -0.10 | -0.13 | 0.16 | -0.06 | -0.08 | -0.07 | -0.11 | 0.03 |
| Tax % | -16.67% | -33.33% | 0.00% | -7.69% | -10.00% | -7.69% | -31.25% | -16.67% | -12.50% | -14.29% | -9.09% | -33.33% |
| Net Profit | -0.05 | -0.02 | -0.04 | -0.13 | -0.09 | -0.12 | 0.21 | -0.05 | -0.07 | -0.06 | -0.09 | 0.04 |
| EPS in Rs | -0.09 | -0.03 | -0.07 | -0.22 | -0.15 | -0.21 | 0.36 | -0.09 | -0.12 | -0.10 | -0.15 | 0.07 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.94 | 17.18 | 8.10 | 5.59 | 6.59 | 6.33 | 0.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 16.50 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.80 | 0.18 | 0.30 | 0.20 | 0.20 |
| Operating Profit | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.30 | -0.80 | -0.18 | -0.30 | -0.20 | -0.20 |
| OPM % | 2.60% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | |||||
| Other Income | 0.10 | 0.08 | 0.21 | 0.25 | 0.26 | 0.00 | 1.33 | -3.35 | 0.00 | 0.25 | 0.01 | 0.13 |
| Interest | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0.00 | 0.12 | 0.16 | 0.13 | 0.16 |
| Depreciation | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.01 | 0.01 | 0.03 | -3.50 | -1.28 | 0.67 | -4.24 | -0.30 | -0.21 | -0.32 | -0.23 |
| Tax % | 100.00% | 0.00% | 100.00% | 0.00% | 7.43% | 0.00% | -7.46% | 0.00% | -10.00% | -33.33% | -12.50% | |
| Net Profit | 0.01 | 0.01 | 0.00 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.28 | -0.18 |
| EPS in Rs | 0.02 | 0.02 | 0.00 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.48 | -0.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | % | 12% | % | -260% | ||
| Stock Price CAGR | % | 22% | -1% | -16% | ||
| Return on Equity | % | % | % | % |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves | 1.21 | 1.21 | 1.19 | 1.18 | 1.18 | -2.64 | -3.92 | -3.20 | -7.42 | -7.22 | -7.34 | -7.62 |
| Borrowings | 9.25 | 9.01 | 9.94 | 11.32 | 5.35 | 2.85 | 2.50 | 1.32 | 1.33 | 1.36 | 1.49 | 1.80 |
| Other Liabilities | 2.32 | 2.34 | 3.97 | 5.01 | 9.46 | 1.52 | 1.20 | 0.91 | 0.31 | 0.06 | 0.08 | 0.04 |
| Total Liabilities | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
| Fixed Assets | 10.08 | 10.27 | 12.68 | 12.45 | 11.99 | 4.78 | 3.64 | 4.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 8.35 | 7.94 | 8.27 | 10.91 | 9.85 | 2.80 | 1.99 | 0.45 | 0.07 | 0.05 | 0.08 | 0.07 |
| Total Assets | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.39 | 0.83 | 2.46 | 0.89 | -0.95 | -11.34 | -0.29 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 |
| Cash from Investing Activity | -2.44 | -0.21 | -3.18 | -0.37 | -0.28 | 11.24 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activity | 2.18 | -0.78 | 0.63 | 1.04 | -0.29 | -0.02 | -0.03 | -0.01 | 0.00 | 0.15 | 0.25 | 0.16 |
| Net Cash Flow | 0.12 | -0.15 | -0.09 | 1.56 | -1.51 | -0.12 | -0.21 | 0.20 | 0.01 | -0.02 | 0.02 | 0.00 |
| Free Cash Flow | -2.06 | 0.62 | -0.73 | 0.36 | -1.23 | -0.10 | -0.17 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 |
| CFO/OP | 41% | 189% | 203% | 102% | -164% | 342% | 126% | -70% | -1% | 94% | 110% | 80% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57.74 | 53.87 | 56.30 | 102.74 | 135.81 | 79.20 | 91.11 | 34.53 | ||||
| Inventory Days | 77.67 | 46.15 | 55.54 | 181.31 | 832.82 | 81.53 | 46.98 | 197.71 | 0.00 | |||
| Days Payable | 43.12 | 41.39 | 49.24 | 63.34 | 436.97 | 41.89 | 28.91 | 342.19 | ||||
| Cash Conversion Cycle | 92.30 | 58.62 | 62.60 | 220.71 | 531.66 | 118.84 | 109.18 | -109.95 | ||||
| Working Capital Days | 24.71 | -6.46 | -29.53 | -139.69 | -317.99 | -72.00 | -66.89 | -764.53 | ||||
| ROCE % | 3.39% | 2.84% | 2.00% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.90% | -1,266.67% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 28.24% | 28.24% | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 29.61% | 25.85% | 25.85% | 25.85% |
| Public | 71.76% | 71.75% | 70.40% | 70.39% | 70.39% | 70.39% | 70.39% | 70.39% | 70.38% | 74.15% | 74.15% | 74.14% |
| No. of Shareholders | 18,638 | 18,628 | 18,595 | 18,584 | 18,536 | 18,509 | 18,514 | 18,481 | 18,488 | 18,468 | 18,446 | 18,444 |
Fundamentals
Market Cap₹ 8.80 Cr.
Current Price₹ 15.0
Book Value₹ -3.03
ROCE-1,267 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)-260%
Standalone figures.
Valuation
Market capRs 9 Cr
Enterprise valueRs 11 Cr
Price to book-4.97x
Earnings yield-2.05%
P/B, 3-year average-7.20x
P/E, 5-year average5.33x
P/B, 5-year average-4.43x
Profitability
ROE17.18%
ROCE-1266.67%
ROA-373.33%
ROE, 3-year average14.88%
ROCE, 3-year average-1266.67%
ROA, 3-year average-341.11%
ROE, 5-year average-141.45%
ROCE, 5-year average-492.61%
ROA, 5-year average-236.11%
Tax rate12.50%
Other income / net worth-0.56%
Per share
EPS (TTM)Rs -0.31
EPS (latest year)Rs -0.48
EPS (latest quarter)Rs 0.07
EPS, 3-year averageRs -0.39
EPS, 5-year averageRs -1.43
Book value per shareRs -3.03
Cash flow per shareRs -0.27
Free cash flow per shareRs -0.27
Efficiency
Creditor days342 days
Cash conversion cycle-110 days
Working capital days-765 days
Leverage
Total debtRs 2 Cr
Cash and bankRs 0 Cr
Net debtRs 2 Cr
Debt to equity-1.02x
Interest coverage-0.44x
Owners' fund to total sources-2528.57%
Debt to assets2571.43%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 6 Cr
ReservesRs -8 Cr
Shareholders' fundsRs -2 Cr
Total assetsRs 0 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)0.58
Ownership
Promoter holding25.85% (-3.76 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 524604 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +24.1% | -2.8% | +26.9 pts |
| 1 month | +21.0% | -6.8% | +27.8 pts |
| 3 years | +3.2% | +14.2% | -11.0 pts |
| 5 years | +168.6% | +27.9% | +140.7 pts |
Red flags
F-score 2 of 6| serious | Negative equity Shareholders' equity is negative |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr.
Net profit ₹0 Cr +180.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Adline Chem Lab Ltd?
Adline Chem Lab Ltd (524604) has a market capitalisation of Rs 8.80 Cr. at the 2026-09-24 close.
What were Adline Chem Lab Ltd's latest quarterly results?
In the Jun 2026 quarter, Adline Chem Lab Ltd sales was Rs 0 Cr and net profit was Rs 0 Cr.